Weeks Defies Years of Jurisprudence, Allowing Innovator Liability for Generic Drugs

Last week the Alabama Supreme Court adopted brand-name manufacturer liability for a generic drug sold by another company, becoming the first state supreme court to do so. Wyeth, Inc. v. Weeks, No. 1101397 (Ala. Jan. 11, 2013). The court held that a generic drug user could foreseeably rely on a brand-name drug warning and maintain a failure to warn claim against the brand-name manufacturer, even when the plaintiff did not ingest that manufacturer’s drug.


Danny and Vicki Weeks filed suit against four pharmaceutical companies in federal district court, alleging injury from long-term use of metoclopramide, the generic form of Reglan. They claimed that Mr. Weeks ingested generic metoclopramide manufactured by Teva and Actavis. Plaintiffs also named Wyeth and Schwarz, the manufacturers of brand-name Reglan, even though they never alleged that Mr. Weeks ingested the brand-name drug. Instead, they sued Wyeth and Schwarz on a theory that the brand-name manufacturers had a duty to warn all users of the drug based on federal requirements that all generic labels be identical to the brand-name label. Faced with this question and conflicting precedent, the district court certified the question to the Alabama Supreme Court, specifically...

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

Published In:

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.